Pharmacological profiles of R-96544, the active form of a novel 5-HT2A receptor antagonist R-102444

European Journal of Pharmacology

Volumn 457, Issue 2-3, 2002, Pages 107-114

  Ogawa, Taketoshi ^a   Sugidachi, Atsuhiro ^a   Tanaka, Naoki ^a   Fujimoto, Koichi ^a   Asai, Fumitoshi ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

5 HT (5 hydroxytryptamine, serotonin); 5 HT2A receptor antagonist; R 102444; R 96544

Indexed keywords

1 [2 [2 (3 METHOXYPHENYL)ETHYL]PHENOXY] 3 (DIMETHYLAMINO) 2 PROPANOL; 4 HYDROXY 2 [2 [2 [2 (3 METHOXY)PHENYL]ETHYL]PHENOXY]ETHYL 1 METHYLPYRROLIDINE; 4 LAUROYLOXY 2 [2 [2 [2 (3 METHOXY)PHENYL]ETHYL]PHENOXY]ETHYL 1 METHYLPYRROLIDINE; ADENOSINE DIPHOSPHATE; ADRENALIN; ANGIOTENSIN; KETANSERIN; M 1; PHENYLEPHRINE; R 102444; R 96544; SARPOGRELATE; SEROTONIN; SEROTONIN 2A ANTAGONIST; SEROTONIN 2B RECEPTOR; UNCLASSIFIED DRUG; (2R,4R) 4 HYDROXY 2 (2 (2 (2 (3 METHOXY)PHENYL)ETHYL)PHENOXY)ETHYL 1 METHYLPYRROLIDINE HYDROCHLORIDE; (2R,4R)-4-HYDROXY-2-(2-(2-(2-(3-METHOXY)PHENYL)ETHYL)PHENOXY)ETHYL-1-METHYLPYRROLIDINE HYDROCHLORIDE; ANTITHROMBOCYTIC AGENT; PYRROLIDINE DERIVATIVE; R-102444; SEROTONIN 2A RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTICLE; ASSAY; BINDING SITE; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; GANGLION BLOCK; GUINEA PIG; HUMAN; HUMAN CELL; HYPERTENSION; ILEUM; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; RABBIT; RAT; RECEPTOR AFFINITY; THROMBOCYTE AGGREGATION INHIBITION; ANIMAL; BLOOD PRESSURE; CAT; DOSE RESPONSE; DRUG EFFECT; INTRAVENOUS DRUG ADMINISTRATION; MACACA; METABOLISM; MOUSE STRAIN; PATHOPHYSIOLOGY; PHYSIOLOGY; SPECIES DIFFERENCE; SPONTANEOUSLY HYPERTENSIVE RAT; SPRAGUE DAWLEY RAT; THROMBOCYTE; THROMBOCYTE AGGREGATION;

ADULT; ANIMALS; BINDING SITES; BLOOD PLATELETS; BLOOD PRESSURE; CATS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERTENSION; INJECTIONS, INTRAVENOUS; KETANSERIN; MACACA FASCICULARIS; MALE; MICE; MICE, INBRED STRAINS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PYRROLIDINES; RABBITS; RATS; RATS, INBRED SHR; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; SPECIES SPECIFICITY;

EID: 0037146931     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02654-7     Document Type: Article

References (36)

1. Arunlakshana O., Schild H. Some quantitative uses of drug antagonists. Br. J. Pharmacol. 14:1956;48-58.
2. Baumgartner H.R., Born G.V. Effects of 5-hydroxytryptamine on platelet aggregation. Nature. 218:1968;137-141.
3. Baumgartner R.A., Wills-Karp M., Kaufman M.J., Munakata M., Hirshman C. Serotonin induces constriction and relaxation of the guinea pig airway. J. Pharmacol. Exp. Ther. 255:1990;165-173.
4. 2B) in rat stomach fundus longitudinal muscle. Br. J. Pharmacol. 112:1994;323-331.
5. 50) of an enzymatic reaction. Biochem. Pharmacol. 22:1973;3099-3108.
6. Cohen M.L., Fuller R.W., Kurz K.D. Evidence that blood pressure reduction by serotonin antagonists is related to alpha receptor blockade in spontaneously hypertensive rats. Hypertension. 5:1983;676-681.
7. 2 receptors in serotonin-induced contractions of nonvascular smooth muscle. J. Pharmacol. Exp. Ther. 232:1985;770-774.
8. 3 receptor antagonist without gastroprokinetic activity. J. Pharmacol. Exp. Ther. 254:1990;350-355.
9. 2 receptors and delays occlusion in a rabbit model of thrombosis. J. Pharmacol. Exp. Ther. 261:1992;202-208.
10. De Clerck F., Herman A.G. 5-hydroxytryptamine and platelet aggregation. Fed. Proc. 42:1983;228-232.
11. 2-receptor antagonist. Agents Actions. 12:1982;388-397.
12. Docherty J.R. Investigations of cardiovascular 5-hydroxytryptamine receptor subtypes in the rat. Naunyn-Schmiedeberg's Arch. Pharmacol. 337:1988;1-8.
13. Drummond A.H., Gordon J.L. Platelet release reaction induced by 5-hydroxytryptamine. J. Physiol. (Lond.). 240:1974;39P-40P.
14. Fozard J.R. Mechanism of the hypotensive effect of ketanserin. J. Cardiovasc. Pharmacol. 4:1982;829-838.
15. 2-serotonergic receptor antagonist. Thromb. Haemost. 65:1991;415-420.
16. Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., Saxena P.R., Humphrey P.P. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev. 46:1994;157-203.
17. 2 antagonist, on the responses to 5-HT in the guinea pig ileum and trachea. Biog. Amines. 5:1988;465-474.
18. 2 receptors in tracheal smooth muscle. Naunyn-Schmiedeberg's Arch. Pharmacol. 333:1986;91-97.
19. 3H]ketanserin. J. Pharmacol. 88:1983;125-130.
20. 3H]ketanserin binding sites associated with nerve terminals in rat brain and with platelets; relation with release of biogenic amine metabolites induced by ketanserin- and tetrabenazine-like drugs. J. Pharmacol. Exp. Ther. 244:1988;310-321.
21. 3H]ketanserin binding sites on human platelets and their role in serotonin release. Eur. J. Pharmacol. 206:1991;39-45.
22. Nagakura Y., Kadowaki M., Tokoro K., Tomoi M., Mori J., Kohsaka M. Pharmacological characterization of FK1052, a dihydropyridoindole derivative, as a new serotonin 3 and 4 dual receptor antagonist. J. Pharmacol. Exp. Ther. 265:1993;728-752.
23. Nilsson T., Longmore J., Shaw D., Pantev E., Bard J.A., Branchek T., Edvinsson L. Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur. J. Pharmacol. 372:1999;49-56.
24. 2-induced aggregation in cat platelets. Blood Coagul. Fibrinolysis. 9:1998;233-240.
25. Ogawa T., Sugidachi A., Asai F., Koike H. Reduced platelet serotonin content in rabbits with dietary hypercholesterolemia. Blood Coagul. Fibrinolysis. 11:2000;313-319.
26. 2 receptor antagonist. J. Pharmacol. Exp. Ther. 262:1992;759-768.
27. 2-selective agonists on cat platelet aggregation. Life Sci. 41:1987;1077-1081.
28. Sharma S.K., Zahradka P., Chapman D., Kumamoto H., Takeda N., Dhalla N.S. Inhibition of serotonin-induced vascular smooth muscle cell proliferation by sarpogrelate. J. Pharmacol. Exp. Ther. 290:1999;1475-1481.
29. Sugidachi A., Asai F., Yoneda K., Iwamura R., Ogawa T., Otsuguro K., Koike H. Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type Gi-linked P2T antagonist, CS-747. Br. J. Pharmacol. 132:2001;47-54.
30. 2 receptors. Atherosclerosis. 132:1997;139-143.
31. Tanaka N., Goto R., Ito R., Hayakawa M., Sugidachi A., Ogawa T., Asai F., Fujimoto K. [2-(ω-Phenylalkyl)phenoxy]alkylamines II: synthesis and selective serotonin-2 receptor binding. Chem. Pharm. Bull. 48:2000;245-255.
32. Tanaka N., Goto R., Ito R., Hayakawa M., Sugidachi A., Ogawa T., Asai F., Fujimoto K. [2-(ω-Phenylalkyl)phenoxy]alkylamines III: synthesis and selective serotonin-2 receptor binding (2). Chem. Pharm. Bull. 48:2000;1729-1739.
33. Vanags D.M., Rodgers S.E., Duncan E.M., Lloyd J.V., Bochner F. Potentiation of ADP-induced aggregation in human platelet-rich plasma by 5-hydroxytryptamine and adrenaline. Br. J. Pharmacol. 106:1992;917-923.
34. 2 serotonergic receptors. J. Pharmacol. Exp. Ther. 218:1981;217-220.
35. Van Nueten J.M., Leysen J.E., Vanhoutte P.M., Janssen P.A. Serotonergic responses in vascular and non-vascular tissues. Arch. Int. Pharmacodyn. Ther. 256:1982;331-334.
36. 2 receptors and brain circulation. J. Cardiovasc. Pharmacol. 16(Suppl. 3):1990;S20-S24.